Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast, Advisory

Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference


Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024 at 1:05 p.m. ET (10:05 a.m. PT).

A live audio webcast of the fireside chat will be available here and will be available for replay for 90 days following the presentation.

About Switch Therapeutics

Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases - affecting the central nervous system, peripheral nervous system and systemic indications ? with significant unmet need. The CASi (Conditionally Activated siRNA) Platform, the company's novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for efficient self-delivery and uptake, potency and duration of effect and cell selective RNAi activity. Switch is based in South San Francisco, California. For more information, connect with Switch on LinkedIn or visit www.switchthera.com.


These press releases may also interest you

at 19:34
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRAtm
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...

at 16:48
Marc Dubrick and Lisa Becharas Win St. Anthony's Triathlon
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...

at 16:30
CYTALUX Real-World Experience Presented at the American Association for Thoracic Surgery 104th Annual Meeting
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...

at 15:40
Brooks Breland Named Leading Lawn and Plant Health Care Expert
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...

at 12:00
OBiO Technology will showcase at American Society of Gene & Cell Therapy
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...

at 12:00
SightMD Pennsylvania Expands Practice with Acquisition of James Lewis, MD
SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD. Through this strategic partnership, Dr. Lewis's practice at 8380 Old York Rd Ste 110, Elkins Park, PA 19027 will expand...

More news about Health...


News published on and distributed by: